Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

247 views

Visitors from

US 53%·

AU 33%·

IN 7%·

GB 2%·

FR 1%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Here's What to Expect From Agilent Technologies’ Next Earnings Report

April 24, 2026 at 08:44 AM EDT

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Agilent Technologies, Inc. (A), headquartered in Santa Clara, California, provides application focused solutions to the life sciences, diagnostics, and applied chemical markets. Valued at $34 billion by market cap, the company offers electronic and bio-analytical measurement, semiconductor, and board testing. The global leader in analytical and clinical laboratory technologies is expected to announce its fiscal second-quarter earnings for 2026 in the near future.

Ahead of the event, analysts expect A to report a profit of $1.41 per share on a diluted basis, up 7.6% from $1.31 per share in the year-ago quarter. The company beat or matched the consensus estimates in three of the last four quarters while missing the forecast on another occasion.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

For the full year, analysts expect A to report EPS of $5.95, up 6.4% from $5.59 in fiscal 2025. Its EPS is expected to rise 10.1% year over year to $6.55 in fiscal 2027.

A stock has underperformed the S&P 500 Index’s ($SPX) 32.2% gains over the past 52 weeks, with shares up 9% during this period. However, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV) 7.7% gains over the same time frame.

On Feb. 25, A reported its Q1 results, and its shares closed down more than 3% in the following trading session. Its adjusted EPS of $1.36 fell short of Wall Street expectations of $1.37. The company’s revenue was $1.8 billion, meeting Wall Street forecasts. A expects full-year adjusted EPS in the range of $5.90 to $6.04, and revenue ranging from $7.3 billion to $7.5 billion.

Analysts’ consensus opinion on A stock is bullish, with a “Strong Buy” rating overall. Out of 16 analysts covering the stock, 11 advise a “Strong Buy” rating, one suggests a “Moderate Buy,” and four give a “Hold.” A’s average analyst price target is $162.64, indicating an ambitious potential upside of 42.1% from the current levels.

On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

More news from Barchart

Report this content

If you believe this article contains misleading, harmful, or spam content, please let us know.

Report this article